Back to top
more

MEI Pharma (MEIP)

(Delayed Data from NSDQ)

$3.05 USD

3.05
8,066

-0.05 (-1.61%)

Updated Apr 26, 2024 03:44 PM ET

After-Market: $3.08 +0.03 (0.98%) 7:20 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value F Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for MEIP

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

MEI Pharma, Inc. [MEIP]

Reports for Purchase

Showing records 1 - 20 ( 141 total )

Company: MEI Pharma, Inc.

Industry: Medical - Drugs

Record: 1

11/22/2023

Company Report

Pages: 6

Optimized Entry and Exit Levels for MEIP 112223

Provider: Stock Traders Daily

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: MEI Pharma, Inc.

Industry: Medical - Drugs

Record: 2

03/21/2023

Company Report

Pages: 6

Dropping Coverage

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: MEI Pharma, Inc.

Industry: Medical - Drugs

Record: 3

02/13/2023

Company Report

Pages: 7

Voruciclib and ME-344 Look to Drive a New Narrative for MEI; Reit. Buy and Lowering our PT to $2

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: MEI Pharma, Inc.

Industry: Medical - Drugs

Record: 4

11/16/2022

Company Report

Pages: 7

Zandelisib Data Expected at ASH ’22, As Other Clinical Assets Move Forward; Reit. Buy and $5 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: MEI Pharma, Inc.

Industry: Medical - Drugs

Record: 5

09/12/2022

Company Report

Pages: 6

Zandelisib Continues to Move Forward on a Longer Path Towards Approval; Reit. Buy and $5 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: MEI Pharma, Inc.

Industry: Medical - Drugs

Record: 6

05/26/2022

Company Report

Pages: 7

Considerations on the Future of Zandelisib Following FDA AdCom; Reit Buy and $5 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: MEI Pharma, Inc.

Industry: Medical - Drugs

Record: 7

03/25/2022

Company Report

Pages: 7

Zandelisib Story Requires Extra Patience, But Not All Hope is Lost; Reit. Buy and Lowering PT to $5

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: MEI Pharma, Inc.

Industry: Medical - Drugs

Record: 8

02/15/2022

Company Report

Pages: 7

Zandelisib NDA Remains Central Focus; Reit. Buy and $10 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: MEI Pharma, Inc.

Industry: Medical - Drugs

Record: 9

11/30/2021

Daily Note

Pages: 5

Positive TIDAL Data Further Differentiates Zandelisib Among PI3Kä Inhibitors

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 5.00

Research Provided by a Third Party

Company: MEI Pharma, Inc.

Industry: Medical - Drugs

Record: 10

11/12/2021

Company Report

Pages: 7

Awaiting TIDAL to Make a Positive Splash in FL; Reit Buy and PT $10

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: MEI Pharma, Inc.

Industry: Medical - Drugs

Record: 11

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for MEIP

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: MEI Pharma, Inc.

Industry: Medical - Drugs

Record: 12

09/03/2021

Company Report

Pages: 7

Top-Line TIDAL Data Remains Central Focus; Reit Buy and $10 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: MEI Pharma, Inc.

Industry: Medical - Drugs

Record: 13

06/11/2021

Daily Note

Pages: 4

Zandelisib Showcases Efficacy Across FL and Other B-cell Malignancies During ASCO ’21

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: MEI Pharma, Inc.

Industry: Medical - Drugs

Record: 14

05/07/2021

Company Report

Pages: 7

TIDAL and COASTAL Programs Set to Advance Zandelisib in 2021; Reit Buy and $10 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: MEI Pharma, Inc.

Industry: Medical - Drugs

Record: 15

04/14/2021

Daily Note

Pages: 4

Preclinical Data For Vorociclib Presented At AACR 2021 Highlights Its Potential In KRAS-mutant Cancers

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: MEI Pharma, Inc.

Industry: Medical - Drugs

Record: 16

02/08/2021

Daily Note

Pages: 5

PI3K Inhibitor Takes the Podium; Ukoniq Readthrough to Zandelisib

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: MEI Pharma, Inc.

Industry: Medical - Drugs

Record: 17

02/05/2021

Company Report

Pages: 7

A Tidal Wave of Milestones Expected in 2021; Reit Buy and $10 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: MEI Pharma, Inc.

Industry: Medical - Drugs

Record: 18

01/07/2021

Daily Note

Pages: 3

Kicking off 2021 with Positive Clinical Program Updates; Reit Buy and $10 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: MEI Pharma, Inc.

Industry: Medical - Drugs

Record: 19

11/11/2020

Company Report

Pages: 6

Primary Focus on Zandelisib Development Programs; Reit Buy and $10 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: MEI Pharma, Inc.

Industry: Medical - Drugs

Record: 20

09/10/2020

Company Report

Pages: 6

MEIP Finishing FY20 Strong With Notable Catalysts Going Into FY21; Reit Buy and $10 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party